Ipratropium bromide 500micrograms/2ml nebuliser liquid unit dose vials

Objectives: There is a scarcity of pharmacological treatments that efficiently address lung injury in individuals experiencing acute respiratory distress syndrome (ARDS). Early inhaled corticosteroids and ipratropium may reduce pulmonary inflammation and injury of the lungs, minimizing the risk of ARDS. Method: This is a double-blinded randomized control trial conducted on patients at risk of ARDS. Patients were randomly allocated into two groups; the intervention group (63 patients) were administered aerosolized budesonide and ipratropium bromide, and the control group (56) were administered a placebo every eight hours for five days. Alteration in oxygen saturation divided by inspired oxygen (Fio2) (S/F) after five days was the primary outcome. Secondary outcomes included ARDS occurrence, mechanical ventilation (MV) requirement, hospital stay duration, and mortality rates. Results: Of the 604 screened, only 119 patients were included. The intervention group (63 patients) S/F ratio recovered versus the fall of the control group. Both groups had similar organ dysfunction and 28-day mortality. The intervention group had significantly (p Conclusions: The administration of inhaled budesonide and ipratropium bromide improved oxygenation, as assessed by the S/F ratio, and significantly reduced the rate of ARDS development and the requirement of MV versus the control group. Larger multi-center trials including diverse patient populations are needed to validate these results.

Abstract licence: CC BY

ObjectiveTo evaluate the effectiveness of a new device (SOBIstat-F®) for bronchodilator administration via pMDI compared with the conventional method.IntroductionProtocols for managing severe asthma exacerbations include bronchodilators (short-acting beta-2 agonists and ipratropium bromide) administered by nebulizer or pressurized metered-dose inhaler(pMDI) with a valved holding chamber, corticosteroids IV, and magnesium sulfate IV.MethodsA randomized superiority clinical trial was conducted in children with severe acute asthma at the emergency department. Patients were assigned to one of the following groups: pMDI-SOBx, in which they received bronchodilators in pMDI through the SOBIstat-F® device, or in pMDI with oxygen via cannula or mask (pMDI-OxStand). The primary outcome was the need for hospitalization at the end of 8 h.Results84 patients participated in the study, of which 43 were treated with the pMDI-SOBx device and 41 with pMDI-OxStand. There were no baseline differences between the groups. Children treated with pMDI-SOBx had a lower hospitalization rate compared to those with pMDI-OxStand (9.3% vs. 26.8%, respectively, p = 0.036; absolute risk difference: -17.5% [95% CI: -33.6 to -1.4] and OR: 0.26 [95% CI: 0.08-0.91]). Additionally, a significant clinical improvement (pulmonary score) was observed from 90 min (p p ConclusionsFor the first time, bronchodilator administration using the SOBIstat-F® device was more effective than the conventional method in reducing hospitalizations and improving the clinical condition of children with severe asthma exacerbations.

Abstract licence: CC BY